Eli Lilly to Reduce List Prices for Generic Insulins in 2022
September 28, 2021September 28, 2021
September 28, 2021 – Qulipta® (atogepant) from AbbVie has received FDA approval for the preventive treatment of episodic migraine in adults.
- It is the first oral medication in a class of drugs called CGRP receptor antagonists to be specifically developed for this use.
- Recommended dosing is 10mg, 30mg, or 60mg once daily, taken by mouth with or without food.
- Qulipta has launched at a wholesale acquisition cost (WAC) of $991 per 30 tablets.